Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.2584
+0.00843.36%
Post-market: 0.26210.0037+1.43%19:59 EDT
Volume:340.56K
Turnover:86.43K
Market Cap:7.87M
PE:-0.07
High:0.2598
Open:0.2560
Low:0.2500
Close:0.2500
52wk High:2.98
52wk Low:0.1901
Shares:30.44M
Float Shares:28.51M
Volume Ratio:0.60
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:1.02
PE(LYR):-0.01

Loading ...

Aimia Seeks AIM Listing to Boost Liquidity and Investor Reach

TIPRANKS
·
Aug 18

M.P. Evans cuts share count with latest buyback on AIM

TIPRANKS
·
Aug 18

AIM-Listed Pulsar Group hit with High Court petition by HMRC

cityam
·
Aug 18

Caledonian Holdings Adjusts AIM Admission Timetable for Fundraising Shares

TIPRANKS
·
Aug 18

Dotlines accelerates telecom and digital finance expansion post-AIM listing

TIPRANKS
·
Aug 17

Next 15 Seeks AIM Admission for New Shares Linked to Savanta Acquisition Earnout

TIPRANKS
·
Aug 15

Oberon AIM VCT Investment Manager Increases Personal Stake

TIPRANKS
·
Aug 13

Aimia Inc. (AIM) Gets a Buy from Jefferies

TIPRANKS
·
Aug 13

Unicorn AIM VCT Cancels Shares in New Buyback Move

TIPRANKS
·
Aug 12

Hargreave Hale AIM VCT trims share capital with latest buyback

TIPRANKS
·
Aug 12

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

GlobeNewswire
·
Aug 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR)

TIPRANKS
·
Aug 12

AIM Vaccine Sets August Board Meeting to Approve Interim Results and Consider Dividend

TIPRANKS
·
Aug 12

Unicorn AIM VCT Raises £30.6m and Expands Share Capital Through AIM-Focused Equity Offer

TIPRANKS
·
Aug 12

M.P. Evans Cuts Share Count With Latest Buyback on AIM

TIPRANKS
·
Aug 12

AIM ImmunoTech CEO Urges Biodefense Military Integration

TIPRANKS
·
Aug 11

AIM ImmunoTech Q2 EPS $-0.43

THOMSON REUTERS
·
Aug 10

Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

Dow Jones
·
Aug 10

AIM ImmunoTech Q2 FY26 Net Loss Widens 35.6% to USD 3.79 Million

Reuters
·
Aug 08

AIM ImmunoTech Signs Manufacturing Pact with Sterling Pharma, Cost Seen at $1.5 Million

Reuters
·
Aug 07